A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the efficacy and safety BIND-014 in patients with metastatic castration-resistant prostate cancer (mCRPC).
CRPC|Prostate Cancer
DRUG: BIND-014
To determine the efficacy of BIND-014 as measured by radiographic progression-free survival (rPFS) in patients with chemotherapy-na√Øve metastatic CRPC, Number of patients with a progression-free survival of 6 months, Patients will be followed for the duration of treatment, an expected average of 24 weeks
To assess the safety and tolerability of BIND-014, Number of patients who experience adverse events, Patients will be followed for the duration of treatment, an expected average of 24 weeks
The purpose of this study is to evaluate the efficacy and safety BIND-014 in patients with metastatic castration-resistant prostate cancer (mCRPC).